Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research Progress
Cold-inducible RNA-binding protein (CIRBP), also known as CIRP or A18 hnRNP, is an 18kDa cold shock protein that is a member of the glycine-rich RNA-binding protein family, and was originally found in mammalian cells. As a multifunctional protein, CIRBP plays a vital role in many biological activities, such as tumorigenesis, hypothermic injury, ultraviolet radiation-related inflammation, clock gene regulation and limb regeneration. Furthermore, there is increasing evidence that CIRBP is a pro-inflammatory cytokine that induces various inflammatory responses.
CIRBP and OSCC
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of the head and neck. Recent studies have confirmed that CIRBP expression is increased in OSCC, and high expression levels of CIRBP or toll-like receptors 4 (TLR4) are associated with shorter survival rates. Moreover, the study found that the expression levels of CIRBP and TLR4 are very similar. In conclusion, expression of CIRBP and TLR4 is increased in OSCC and plays an important role in long-term prognosis. Identification of these two genes can provide clues about the regulatory mechanisms of OSCC and suggest that their up-regulation in OSCC etiology can also serve as a prognostic marker.
CIRBP and HCC
Most hepatocellular carcinoma (HCC) develops in the context of chronic liver inflammation. Oxidative stress is thought to play a major role in the pathogenesis of HCC development. Sakura et al examined whether CIRBP controls the accumulation and development of reactive oxygen species (ROS) in HCC by using a mouse model of hepatocarcinogenesis and human liver samples. CIRBP expression, ROS accumulation and CD133 expression were increased in the liver of tumor-harboring mice. CIRBP deficiency reduced the production of interleukin-1b and interleukin-6 in Kupffer cells, ROS accumulation and CD133 expression, resulting in reduced hepatocarcinogenesis. Thioacetamide treatment enhanced hepatic expression of CD133 and phosphorylation signal transduction and activator of transcription 3 (STAT3), which was prevented by treatment with an antioxidant butylated hydroxyanisole. Interestingly, the risk of human HCC recurrence was positively correlated with CIRBP expression in the liver. CIRBP appears to have important oncogenic functions and its expression may be a useful biomarker for HCC risk prediction.
CIRBP and Neuroinflammation
Neuroinflammation is a critical cascade after cerebral ischemia. Excessive production of pro-inflammatory mediators in ischemia can exacerbate brain damage. It has been determined that CIRBP acts as a novel mediator of brain inflammation by stimulating the production of tumor necrosis factor-α (TNF-α) in microglia under hypoxic/ischemic stress. In CIRBP-deficient mice, the severity of brain damage and stroke inflammation is improved. Neutralizing antisera to CIRBP can attenuate TNF-α release from microglia and apoptosis of neural cell exposed to hypoxia medium. These findings provide new insights of neuroinflammation and the complex pathogenesis of ischemic stroke. Therefore, targeting CIRBP can provide new therapeutic strategies to alleviate brain inflammation and reduce neuronal damage in ischemic stroke.
CIRBP and I/R
Intestinal ischemia-reperfusion (I/R) can occur in both shock and mesenteric occlusive disease, leading to significant morbidity and mortality. In addition to localized injury, intestinal ischemia-reperfusion can cause damage to distal organs, especially the lungs. Increased levels of pro-inflammatory cytokines, myeloperoxidase, and apoptosis are hallmarks of acute respiratory distress syndrome (ARDS). Cindy Cen et al. found that during intestinal I/R intestinal cells undergo apoptosis or necrosis that release CIRBP, which is then by recognizing TLR4/MD2 complex on cell surfaces induces a sterile inflammatory response in the lungs causing ARDS (Fig. 1). That is to say, CIRBP plays a key role in local intestinal inflammation after intestinal I/R, and in enhancing the inflammation of the distal part of the lung I/R lung.

Fig. 1. Schematic model of the role of CIRP during intestinal I/R (Cen et al. Surgery, 2017)
CIRBP and Cushing’s disease
Cushing's disease is caused by a pituitary cortical malnutrition adenoma, and its pathogenesis remains unclear. Recent studies have shown that CIRBP was significantly elevated in adrenocorticotropic hormone tumors. Forced overexpression of CIRBP in the mouse AtT20 pituitary adrenocortical cell line increased corticotroph precursor hormone proopiomelanocortin (POMC) transcription, adrenocorticotropic hormone (ACTH) secretion and cell proliferation. In vivo, CIRBP overexpression promotes mouse cortical trophic tumor growth and enhances ACTH production. In mechanism, CIRBP can promote the proliferation of AtT20 cells by inducing cyclinD1 and decreasing p27 expression through the extracellular regulated protein kinases1/2 (Erk1/2) signaling pathway. Clinically, CIRBP overexpression is significantly associated with Cushing's disease recurrence. CIRBP appears to play an important role in tumorigenesis in Cushing's disease, and its expression may be a useful biomarker for tumor recurrence.
CIRBP and RA
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovitis and other systemic involvement. The pathogenesis of RA is complex and involves a wide range of endogenous pro-inflammatory molecules, including cytokines such as TNF. Seol et al. found that the concentration of CIRBP in serum and synovial of RA patients increased compared with patients with osteoarthritis (OA). In addition, the synovial concentration of CIRBP in RA patients is well correlated with disease activity, namely DAS28-ESR / CRP. Based on these results, CIRBP mediates inflammation and is a potential marker of synovial inflammation.
In conclusion, CIRBP can promote the inflammatory response. In addition, there is growing evidence that they also play a key role in the survival and growth of cancer cells. Therefore, further research on the function of CIBRP will provide a possible direction for the understanding and future treatment of inflammatory diseases and related cancers.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.